Trial
NCT06018506
A Phase I Study of BR108 in Hematological Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
BioRay Pharmaceutical Co., Ltd.
Collaborators
—
Condition
Hematologic Malignancy
Intervention
BR108 injection
Why stopped
Adjustment of Company R\&D strategy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-21